Aim Lynch syndrome (LS) accounts for 2-4% of all colorectal cancer (CRC) cases, and is associated with an increased risk of developing metachronous colorectal cancer (mCRC). The role of extended colectomy in LS CRC is controversial. There are limited studies comparing the risk of mCRC following segmental colectomy and extended colectomy. The objective of this systematic review is to evaluate the risk of developing mCRC following segmental and extended colectomy for LS CRC and endoscopic compliance.
Introduction
Lynch syndrome (LS) is a dominantly inherited cancer predisposition syndrome. It is the most common cause of inherited colorectal cancer (CRC), accounting for 2-4% of CRC cases [1, 2] . The condition is characterized by a lifetime risk of CRC by the age of 70 of between 27% and 45% [3, 4] . There is an additional increased risk of developing cancer in other sites, including endometrium, ovary, stomach and urinary tract [3, 4] .
A defect in one of the mismatch repair (MMR) genes (MLH1, MSH2, MSH6 or PMS2) or an epi-mutation in EPCAM, which leads to silencing of MSH2, is the cause of LS [5] . Lifetime cancer risk varies depending on the gene affected, with MLH1 and MSH2 mutation conferring the highest cancer risk [4, 5] . Germline mutations in the MMR genes lead to the inability to repair certain DNA replication errors. The resulting effect is a predisposition to early onset of various cancers, especially CRC, the hallmark of which is microsatellite instability [5, 6] .
Surveillance for bowel cancer by regular colonoscopy is essential to reduce the lifetime risk of developing CRC in LS sufferers. The current guidelines recommend 1-2-yearly colonoscopy in affected individuals [7] . In the event of occurrence of CRC, the appropriate extent of surgical resection has also been controversial, due to the elevated risk of developing metachronous colorectal cancer (mCRC) and the resulting need for future surgical resection. In theory, extended resection will reduce the risk of mCRC; however, this option has to be balanced with the increased morbidity associated with extended resection and potentially poorer function.
There have been no randomized control trials comparing segmental and extended resection in management of LS-related CRC. The evidence for extended resection arises largely from retrospective studies and Level III expert recommendation. Regular endoscopic surveillance of the remaining colon or rectum is strongly recommended in either case [8] .
The primary aim of this systematic review and metaanalysis is to evaluate the risk of developing mCRC following limited (segmental) and extended colectomy in patients with LS. We also aim to evaluate the compliance with endoscopic surveillance and AJCC staging of metachronous cancer at the time of diagnosis.
Methods
A systematic review was performed in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [9] .
Search strategy and information sources
The search strategy was designed by two authors (CA and SA) according to the PRISMA guidelines. The following databases were searched for articles: Embase (1950 to present), MEDLINE from PubMed (1950 to present), Google Scholar and the Cochrane Database of Systematic Reviews.
The search terms were devised to cover LS, mCRC and surgery or colectomy. This was performed by using the following text words (including their synonyms/ variants) and Medical Subject Headings (MESH terms): 'metachronous', 'colorectal', 'neoplasms', 'hereditary non-polyposis colorectal cancer', 'Lynch syndrome', 'colectomy' and 'bowel resection'. The search terms were combined using the Boolean AND/OR operators.
Articles were also sought by hand-searching the reference lists of the selected articles and were included if they met the inclusion criteria. The last search date was 15 January 2016.
Study selection
All articles published in English between 1950 and January 2016 were included in the review. Other inclusion criteria were: studies which reported CRC in patients with LS who underwent treatment in the form of surgical resection or colectomy (segmental, subtotal or total) and subsequent development of mCRC. Studies were included if the patients had proven germline mutation in one of the five genes known to alter MMR function.
Exclusion criteria included: case reports, conference abstracts and review articles. We also excluded studies that did not specify the management of the CRC (i.e. polypectomy or surgery) or the extent of surgical resection (segmental or extended) for the index CRC or mCRC. Studies that reported mCRC in patients from families meeting the Amsterdam criteria, without evidence of a germline mutation affecting MMR status, were also excluded.
Two reviewers (CA and SA) independently performed the searches. Each screened titles and abstracts for relevance and excluded studies that did not meet the inclusion criteria. Differences in selected studies were discussed between the two reviewers and a consensus was reached. In the case of dispute, senior reviewers acted as adjudicators (SC and AL).
Data collection
The following data were extracted from the selected studies: year of publication, authors' names, countries and institutions, number of patients, patient demographics, site of index cancer, type of colectomy, duration of endoscopic follow-up, rate of mCRC, endoscopic compliance, stage of metachronous cancer and interval between index cancer and mCRC. For the purpose of this study, segmental resection includes: all hemicolectomies, anterior resection of the rectum and abdominoperineal excision of the rectum. Extended colectomy was defined as either subtotal colectomy with ileosigmoid anastomosis or total colectomy with ileorectal anastomosis. Panproctocolectomy or restorative proctocolectomy were not included as these should completely abolish the risk of mCRC by removing the entire large bowel.
Quality assessment and bias
The quality of the studies was assessed by two authors (CA and SA) using a Modified Newcastle-Ottawa Scale (NOS) for cohort studies. This was evaluated by examining three factors: patient selection, comparability of segmental and extended colectomy and assessment of outcome (in this case mCRC). The maximum available score for each study is nine points.
Statistical and sub-group analyses
Data from the included studies were summarized and collated in a Microsoft Excel spreadsheet (Microsoft Redmond, Washington, USA). Basic descriptive statistics such as percentages and weighted averages were used to summarize the data. For data analysis, Microsoft Excel and the software package RevMan 5 version 5.3.5 (The Cochrane Collaboration, http://www. cc-ims.net/RevMan) were used. The odds ratio (OR) of developing mCRC in segmental versus extended colectomy was calculated for each study using a random effect model. The confidence interval (CI) was set at 95% and a P-value of 0.05 or less was deemed statistically significant. In addition, sub-group analyses based on study quality using the validated NOS as well as study size (number of patients in study) were carried out.
Results
Figure 1 details the study selection flow chart. The search strategy retrieved a total of 324 studies, of which 312 were identified electronically and 12 were obtained by searching the references of retrieved articles. Of these, 295 were excluded as they did not meet the eligibility criteria. Of the 29 remaining studies, 17 were excluded as they did not specify the type of treatment for the index CRC (n = 12), were systematic reviews (n = 2), case reports (n = 1) or the cohort studied was not specifically LS (n = 2), leaving a total of 12 studies. Of these, six were excluded because they reported mCRC in patients from families meeting the Amsterdam criteria only, leaving a total of six studies which were examined fully and included in the data synthesis. One of these studies was excluded from the meta-analysis as it only reported rates of mCRC after segmental colectomy for rectal cancer and did not offer a comparative mCRC rate for the total colectomy group.
Study characteristics
Across the six original studies, a total of 871 patients with LS underwent bowel resection (segmental, subtotal or total colectomy) for CRC (Table 1) . Across the studies, the average age at the time of index operation was 36.4 years and 35.1% of the subjects were men. A total of 705 (80.9%) and 166 (19.1%) patients underwent segmental and extended colectomy respectively. The weighted average duration of follow-up was 91.2 months.
All the included studies were retrospective reviews of prospectively collected data from family cancer databases/registries. Three studies [10] [11] [12] reported mCRC in patients with germlime mutation in any of the four MMR genes. Two studies [13, 14] reported on patients with MLH1 and MSH2 gene mutations only. Aronson et al. [15] reported mCRC in individuals less than 35 years old with proven mutation in any of the four MMR genes.
Of the six studies, one scored the maximum nine points (Parry et al. [11] ). Another three studies scored eight points (Win et al. [12] , Natarajan et al. [13] , Stupart et al. [14] ) whilst two scored seven points (De Vos tot Nederveen et al. [10] and Aronson et al. [15] ; Table 2 ).
Follow-up and rate of metachronous cancer
The average (weighted mean) length of follow-up was 91.7 months (range 74. . In this period, mCRC occurred in 19.6% (n = 171) of the total population after colectomy (Table 3 ). The rate of mCRC was 22.8% among patients who underwent segmental colectomy and 6% in those who had extended colectomy. Using the random effect model on the five out of six studies ( Fig. 2) which adequately compared the two types of resection, the segmental colectomy group were more than four times more likely than the extended colectomy group to develop mCRC (OR 4.02, 95% CI: 2.01-8.04, P < 0.0001).
Frequency of endoscopic surveillance and metachronous cancer
Endoscopic follow-up was reported in three of the six studies. Parry et al. [11] reported the frequency of colonoscopy or sigmoidoscopy in 57 patients who developed mCRC. Of these, 77.2% (44) were undergoing 1-2-yearly endoscopic surveillance. Similarly, Win et al. [12] reported that 78.9% of patients who developed mCRC underwent 1-2-yearly surveillance colonoscopy. In the Stupart et al. study [14] , two of the eight mCRCs in the segmental colectomy group were diagnosed in patients who developed symptoms less than a year after a normal colonoscopy. The remainder developed in patients who had defaulted colonoscopic surveillance for at least 2 years. In the extended colectomy group, one mCRC developed a year after a normal surveillance sigmoidoscopy and the other in a patient who had defaulted surveillance sigmoidoscopy for 4 years.
Sensitivity analysis and publication bias
Sensitivity analysis for the odds of developing mCRC after segmental and extended colectomy was performed to evaluate the stability of the result. When the largest three studies were analysed (Fig. 3) , the risk of mCRC was greater in the segmental group (OR 7.07, 95% CI: 2.76-18.12, P < 0.0001). Similarly, analysis of the top three studies on the basis of the NOS assessment also generated a similar result (OR 6.28, 95% CI: 2.61-15.10, P = 0.0001; Fig. 4) . Publication bias could not be assessed because there fewer than 10 studies were included.
Discussion
The findings of this systematic review and meta-analysis are that CRC patients with LS who have a segmental colectomy are four times more likely to develop mCRC than patients who have extended colectomy. This is also about four times more than is described in sporadic CRC overall [16] . The sub-group analyses of the largest published studies and the highest-quality studies showed higher odds of 7.3 and 6.8, respectively. Furthermore, mCRC occurred in some patients after SEGC despite adequate postoperative endoscopic surveillance (1-2-yearly). Although segmental resection remains the mainstay of managing sporadic CRC, given the potential for mCRC, extended resection such as subtotal colectomy or total colectomy with ileorectal anastomosis should be considered and discussed in patients with LS-related CRC [8] . The majority of the recommendations outlining best practice in terms of surgical resection and endoscopic follow up of LS patients come from retrospective studies and Level III recommendation. As yet, there have been no randomized controlled trials comparing segmental resection with extended resection or extended resection with endoscopic surveillance.
In 2013 Henegan and colleagues [17] published a systematic review and meta-analysis of six studies, comparing the rate of metachronous adenoma and carcinoma after segmental and extended resection in patients with hereditary nonpolyposis colorectal cancer (HNPCC). Although the authors demonstrated the mCRC rate to be 23.5% and 6.8% in the segmental and extended groups, respectively, there was no statistical Studies were graded on an ordinal star (*) scoring scale with higher scores indicating studies of higher quality. A study could be awarded a maximum of one star for each numbered item within the selection and outcome categories, and a maximum of two stars could be given for the comparability of the two groups. difference between the two groups. Furthermore, three out of the six studies in their review included patients from families which fulfilled the Amsterdam criteria only, without evidence of MMR deficiency. However, meeting the Amsterdam criteria does not confer definite diagnosis of LS. Indeed, in one study [18] 60% of patients with CRC who came from families fulfilling the Amsterdam criteria did not actually have features of MMR deficiency. Using the Amsterdam criteria alone, therefore, gives a very heterogeneous cohort, including not only LS but also conditions such as familial CRC type X, which has a lower rate of mCRC than LS. This is a flaw in the systematic review performed by Henegan and colleagues. Our six-study review of the risk of mCRC in patients with a confirmed genetic diagnosis of LS shows that the rate of mCRC after segmental colectomy compared with extended colectomy was 22.8% and 6%, respectively. Our meta-analysis suggests that extended colectomy decreases the risk of developing mCRC by just over four-fold compared with segmental colectomy in LS CRC. These findings must be interpreted with caution, as it is difficult to quantify patients' background risk of cancer, which might vary with germline mutation, compliance with colonoscopy surveillance, availability of preoperative LS diagnosis and site of the index cancer. Test for overall effect: Z = 4.07 (P < 0.0001) Heterogeneity. Chi 2 = 2.18, df = 2 (P = 0.34); l 2 = 8% The lifetime risk of CRC varies depending on the MMR gene affected, with MLH1 and MSH2 conferring the highest cancer risk [4, 5] . MLH1 and MSH2 mutations lead to a higher degree of penetrance and therefore increased risk of CRC compared with MSH6 and PMS2 mutations [19] . In our systematic review, only two studies [11, 12] reported mCRC according to the individual MMR gene (MLH1, MSH2, MSH6 or PMS2) involved. Parry et al. [11] showed that of the 74 patients with mCRC following segmental colectomy, 33 (45%) were MLH1, 38 (45%) MSH2 and three (4%) MSH6 gene mutation carriers. No mCRC occurred in the PMS2 group, although the numbers were small. Similarly, Win et al. [12] reported mCRC in five (23.8%) MLH1 and 16 (77%) MSH2 mutation carriers. This supports the observation of a more severe phenotype associated with mutation in MLH1 and MSH2. Furthermore, Stupart et al. [14] and Natarajan et al. [13] only reported on patients with MLH1 and MSH2 gene mutations. This could be a potential source of bias as it would suggest that surgical decision-making should be influenced by germline mutation; however, the data are probably not robust enough to make firm recommendations. Further studies quantifying gene-specific risk are warranted.
Several studies have shown that regular colonoscopic surveillance reduces the incidence of LS CRC and its related mortality [20] [21] [22] [23] [24] and a shorter interval (1-2-yearly) between colonoscopies is associated with early tumour stages in patients under surveillance [8, 20, 23] . However, in our study, Parry et al. [11] and Win et al. [12] respectively reported mCRC in 77.2% and 78.9% of SEGC patients undergoing 1-2-yearly postoperative endoscopic surveillance. These findings might be explained by the quality of the endoscopic surveillance and the rapid adenoma-carcinoma sequence associated with LS [20, 22] . Identification and removal of these adenomas via improved endoscopic techniques, such as pan-colonic chromoendoscopy, could decrease the overall risk of developing interval CRC [21, 22, 25] . In addition to regular endoscopic surveillance, the CAPP2 randomized control trial [26] demonstrated that chemoprevention with aspirin reduces the risk of developing CRC in LS. The results of that study showed that after a mean follow-up of 55.7 months, 600 mg of aspirin daily has a protective effect against CRC with an incidence rate ratio of (IRR) of 0.56 (95% CI: 0.32-0.99, P = 0.05). The effect was higher in those taking aspirin for 2 years or more (IRR 0.37, 95% CI: 0.18-0.78, P = 0.008). Chemoprevention in combination with stringent endoscopic surveillance could potentially reduce the risk of mCRC in both segmental and extended colectomy groups.
There are some limitations to this study. It is uncertain if a preoperative diagnosis of MMR mutation was available. Currently, identification of MMR disease status is mainly carried out by performing MMR immunohistochemistry (MMR-IHC) on the resected CRC specimens, followed by further testing if an abnormal result is obtained. However, a preoperative diagnosis of MMR deficiency could facilitate surgical planning and increase the likelihood of more patients being offered extended colectomy [27] . MMR-IHC can be performed on preoperative endoscopic biopsies, and has been shown to be concordant with the postoperative resected sample in LS [28] .
Data on morbidity, bowel functional and quality of life between the two groups were not reported. Haanstra et al. [29] reported no difference in quality of life after partial and subtotal colectomy in LS patients. However, functional outcome such as stool frequency and defaecation problems were worse after subtotal colectomy. Conversely, You et al. [30] reported that median daily stool frequency and quality of life were better after segmental colectomy than subtotal and total colectomy. The extent of resection must also be balanced against the surgical morbidity associated with an extended colectomy [8] , as well as the functional outcome. It is important to highlight that complete elimination of mCRC risk requires a proctocolectomy with end ileostomy or ileoanal pouch. This is associated with significant morbidity and worse functional outcome.
This systematic review is also limited by the paucity of reported variables such as the anatomical site of the index and mCRC, endoscopic follow-up and or chemoprevention. For instance, reporting the location of the index cancer and mCRC might be a significant factor in evaluating the risk of mCRC. It is well known that CRCs in LS are more likely to develop proximal to the splenic flexure. Therefore, it is uncertain if the risk of mCRC differs in patients after a right-sided segmental resection compared with distal segmental resection. Other factors that may influence choice of surgery [e.g. patient preference, mode of surgery (emergency or elective) and WHO performance status] were not reported. Furthermore, the colonoscopy surveillance data from the studies were sparse.
Conclusion
This review was set out to compare the rate of mCRC after segmental and extended colectomy for CRC in LS. We found evidence to suggest that extended resection reduces the risk of mCRC four-fold. Surgeons and patients should be aware of the risk of mCRC after segmental colectomy despite 1-2-yearly postoperative endoscopic surveillance. This risk appears to be higher in MLH1 and MSH2 mutation although more studies are needed to evaluate the risk of mCRC in the individual MMR gene mutations. Therefore, we recommend that CRC patients with MMR gene (MLH1, MSH2, MSH6 or PMS2)-proved LS should be offered the option of extended colectomy; however, age, function, comorbidity and attitudes towards colonoscopy need to be borne in mind. Careful preoperative counselling of the patient is essential.
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